ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor ChemoCentryx, Inc., today announced that it has recognized a novel drug applicant targeting the chemoattractant receptor referred to as ChemR23. This investigational fresh drug, designated CCX832, can be an orally-administered small molecule antagonist of ChemR23, a significant participant in inflammatory disease. The acceptance of CCX832 by GSK triggered a $5 million milestone payment to ChemoCentryx. ‘The acceptance by GSK of CCX832 for clinical development highlights the culmination of the research term in our strategic alliance.‘Lemon is an excellent bleach!’ she says. And lemon with a few sprays of inexpensive vodka are proficient at cleaning counter tops, baking soda for scrubbing, and Borax for washing clothes. ‘The trick,’ says Wertzel, ‘is usually to stop looking in the soap isles for these basic things.’ She says her method is less costly – – and she’s now breathing easier.. Cepheid granted EUA for Xpert Flu A Panel test Cepheid today announced it’s been granted Emergency Use Authorization from the U.S. The FDA has certified Cepheid’s Xpert Flu A Panel to be utilized in laboratories certified beneath the Scientific Laboratory Improvement Amendments to perform ‘moderate complexity’ testing, allowing the check to end up being performed in medical center near-patient settings.